1412 / 1498
• Anthracycline-based chemotherapy as first line treatment for patients
affected with primary bone DLBCL
• A survival benefit of the addition of the anti-CD20 monoclonal
antibody rituximab to CHOP in primary bone DLBCL has not been
demonstrated
•
The survival benefit of adjuvant irradiation after primary R-
chemotherapy is a matter of debate
•
Optimal radiation volumes and doses
Therapeutic issues